Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 53108 [2018-22828]
Download as PDF
<![CDATA[
53108
Federal Register / Vol. 83, No. 203 / Friday, October 19, 2018 / Notices
Controlled substance
Drug code
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Poppy Straw Concentrate ...............................................................................................................................................
Tapentadol .......................................................................................................................................................................
The company plans to import
phenylacetone (8501), and poppy straw
concentrate (9670) to bulk manufacture
other controlled substances for
distribution to its customers. The
company plans to import an
intermediate form of tapentadol (9780)
to bulk manufacture tapentadol (9780)
for distribution to its customers.
The company plans to import
impunities of buprenorphine that have
been determined by DEA to be captured
under drug code (9333) thebaine.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
tetrahydrocannabinol. No other activity
for these drug codes is authorized for
this registration. Placement of these
drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22832 Filed 10–18–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 19, 2018. Such
persons may also file a written request
for a hearing on the application on or
before November 19, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June 4,
2018, Fisher Clinical Services, Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be
registered as an importer of the
following basic class of controlled
substance:
SUPPLEMENTARY INFORMATION:
Drug code
Psilocybin .........................................................................................................................................................................
The company plans to import the
listed controlled substance for clinical
trials.
DEPARTMENT OF JUSTICE
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection;
Comments Requested: 2019 School
Crime Supplement (SCS) to the
National Crime Victimization Survey
(NCVS)
amozie on DSK3GDR082PROD with NOTICES1
BILLING CODE 4410–09–P
Bureau of Justice Statistics,
Department of Justice.
ACTION: 30-Day notice.
AGENCY:
VerDate Sep<11>2014
17:25 Oct 18, 2018
Jkt 247001
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
7437
Schedule
I
The Department of Justice
(DOJ), Office of Justice Programs,
Bureau of Justice Statistics, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 30 days until
November 19, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
SUMMARY:
[OMB Number 1121–0184]
I
I
II
II
II
II
II
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Controlled substance
[FR Doc. 2018–22828 Filed 10–18–18; 8:45 am]
7360
7370
7379
8501
9333
9670
9780
Schedule
E:\FR\FM\19OCN1.SGM
19OCN1
]]>Agencies
[Federal Register Volume 83, Number 203 (Friday, October 19, 2018)]
[Notices]
[Page 53108]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22828]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before November 19, 2018.
Such persons may also file a written request for a hearing on the
application on or before November 19, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
4, 2018, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be registered as an importer of the
following basic class of controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Psilocybin......................... 7437 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance for
clinical trials.
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-22828 Filed 10-18-18; 8:45 am]
BILLING CODE 4410-09-P
